Fig. 6.
From: Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
18F-FDG PET/CT images of the patient ten months after initiation of therapy with erlotinib. MIP image (5a) transaxial CT images (5b–5e) and fused PET/C images (4f–4i) show no significant interval change in size of the left axillary lymph node, anterior abdominal wall lesion and omental/mesenteric deposits and lesion near left ischial tuberosity (arrows) with mild reduction in metabolic activity, overall findings suggestive of stable disease